Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | SYK | P43405 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | HPGD | P15428 | 2/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | TMIGD3 | P0DMS9 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16018387 | 0.87 | L3MBTL1 (0.40) | L3MBTL1HTR2AHTR2C | |
| SCHEMBL12986677 | 0.73 | L3MBTL1 (0.41) | L3MBTL1HTR2AHTR2C | |
| SCHEMBL16018372 | 0.73 | L3MBTL1 (0.39) | L3MBTL1HTR2AHTR2C | |
| SCHEMBL13193196 | 0.71 | L3MBTL1 (0.40) | L3MBTL1HTR2AHTR2C | |
| SCHEMBL4899460 | 0.69 | L3MBTL1 (0.54) | L3MBTL1HTR2AHTR2CHDAC6HSD17B10 | |
| SCHEMBL12986690 | 0.69 | L3MBTL1 (0.50) | L3MBTL1HDAC6RECQLSYKALDH1A1 | |
| SCHEMBL24529242 | 0.68 | L3MBTL1 (0.57) | L3MBTL1HTR2AHTR2CHDAC6SYK | |
| SCHEMBL19086382 | 0.67 | PTK2 (0.43) | L3MBTL1HDAC6MEN1TP53KMT2A | |
| SCHEMBL16828926 | 0.66 | L3MBTL1 (0.50) | L3MBTL1HTR2AHTR2CHDAC6KDM4E | |
| SCHEMBL31108816 | 0.66 | L3MBTL1 (0.54) | L3MBTL1HTR2AHTR2CHDAC6SYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2694500-B1 | SUBSTITUTED IMIDAZOPYRIDINES AND INTERMEDIATES THEREOF | Bayer Pharma AG (DE) | 2015-05-27 | — | — | EP | disclosed |
| US-20140255392-A1 | SUBSTITUTED IMIDAZOPYRIDINES AND INTERMEDIATES THEREOF | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-09-11 | — | — | US | disclosed |
| EP-2694500-A1 | SUBSTITUTED IMIDAZOPYRIDINES AND INTERMEDIATES THEREOF | Bayer Pharma Aktiengesellschaft (DE) | 2014-02-12 | — | — | EP | disclosed |
| WO-2012136531-A1 | SUBSTITUTED IMIDAZOPYRIDINES AND INTERMEDIATES THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140255392-A1 | SUBSTITUTED IMIDAZOPYRIDINES AND INTERMEDIATES THEREOF | FLT4, KDR, VEGFA | L3MBTL1 2809/4885HTR2A 2602/4885HTR2C 2376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.